Table 2.
Characteristics of the patients. Time-to-Chemotherapy before and after 8 weeks.
| Variables | ≤8 weeks | >8 weeks | p | ||
|---|---|---|---|---|---|
| n = 233 | n = 175 | n = 58 | |||
| Age (years) | 59 (±12) | 58 (±12) | 60 (±12) | 0.41 | |
| BMI (kg/m2) | 24.58 (±4.88) | 24.51 (±4.74) | 24.79 (±5.34) | 0.72 | |
| Parity | 1.64 (±1.42) | 1.758 (±1.48) | 1.278 (±1.17) | 0.031 | |
| Mutation | BRCA 1 | 12 (5.1%) | 17 (9.7%) | 4 (2.8%) | 0.8 |
| BRCA 2 | 5 (2.1%) | 1 (0.6%) | 0 | ||
| Hypertension | 42 (24.6%) | 32 (25%) | 10 (23.3%) | 0.82 | |
| Diabetes | 10 (6.2%) | 8 (6.7%) | 2 (4.8%) | 1 | |
| Smoking | 12 (8.5%) | 8 (7.6%) | 4 (10.8%) | 0.8 | |
| Histologic type | Serous | 155 (70.1%) | 116 (70.7%) | 39 (68.4%) | 0.94 |
| Endometrioid | 37 (16.7%) | 27 (16.5%) | 10 (17.5%) | ||
| Clear Cell | 23 (10.4%) | 17 (10.4%) | 6 (10.5%) | ||
| Mucinous | 6 (2.7%) | 4 (2.4%) | 2 (3.5%) | ||
| Grade | 1 | 21 (67.7%) | 16 (72.7%) | 5 (55.6%) | |
| 2 | 7 (22.6%) | 4 (18.2%) | 3 (33.3%) | ||
| 3 | 3 (9.7%) | 2 (9.1%) | 1 (11.1%) | ||
| Lymphovascular space involvement | Yes | 35 (43.8%) | 27 (45.8%) | 8 (38.1%) | 0.54 |
| Stage | Early | 69 (29.6%) | 127 (72.6%) | 37 (63.8%) | 0.2 |
| Advanced | 164 (70.4%) | 48 (27.4%) | 21 (36.2%) | ||
| FIGO Stage | I | 56 (24%) | 36 (20.6%) | 20 (34.5%) | 0.068 |
| II | 17 (7.2%) | 16 (9.1%) | 1 (1.7%) | ||
| III | 141 (60.5%) | 108 (61.7%) | 33 (56.9%) | ||
| IV | 19 (8.1%) | 15 (8.6%) | 4 (6.9%) | ||
| Type of recurrence | Lymph node | 16 (16.7%) | 12 (16.2%) | 4 (18.2%) | 0.84 |
| Peritoneal Carcinomatosis | 63 (65.6%) | 47 (63.5%) | 16 (72.7%) | ||
| Metastasis | 9 (9.4%) | 8 (10.8%) | 1 (4.5%) |
FIGO: International Federation of Gynecology and Obstetrics.